Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novartis Flu Vaccine Nightmare Ends; Worries Over Pharmacovigilance Overreaction Remain

This article was originally published in The Pink Sheet Daily

Executive Summary

As Italy, France, Switzerland and Austria lift bans on two Novartis flu vaccines, Germany’s more sober approach to specific batch suspensions proves more palatable for manufacturers.

You may also be interested in...

Fluad Adjuvant Could Come Under Fire At Advisory Committee

CSL’s (formerly Novartis’) flu vaccine was shown to be non-inferior, but not superior, on immunogenicity endpoints compared to an unadjuvanted vaccine in individuals ages 65 years and older.

Germany’s Vaccine Industry In Danger Of Disappearing, Says GSK

GSK believes detrimental government policies such as reference pricing and tendering in the vaccines sector are threatening this part of the pharmaceutical industry, and patient health.

Novartis Flu Vaccine Problems Highlight Lack Of European Co-ordination

Quality issues that have seen two Novartis influenza vaccines suspended in a number of European countries have highlighted the shortfalls of a co-ordinated European approach to such problems.

Related Content


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts